Study to test Apremilast (CC-10004) in subjects with Plaque Psoriasis

• Research type

  Research Study

• Full title

  A phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, In Subjects with Moderate to Severe Plaque Psoriasis

• IRAS ID

  113017

• Contact name

  Vincent Piguet

• Sponsor organisation

  Celgene Corporation

• Eudract number

  2012-000859-14

• ISRCTN Number

  to be registered

• Research summary

  Psoriasis is a skin disease that causes red skin lesions. Chronic moderate to severe (affects over 5% of the body) Psoriasis is normally treated with injections under the skin and tablets taken orally. Celgene Corportion has developed a new tablet (Apremilast CC-10004) that may be better tolerated and have less side effects than current oral agents. The aim of this study is to test the safety and efficacy of this new product.

• REC name

  Wales REC 2

• REC reference

  12/WA/0365

• Date of REC Opinion

  20 Dec 2012

• REC opinion

  Further Information Favourable Opinion